000106602 001__ 106602
000106602 005__ 20220425105235.0
000106602 0247_ $$2doi$$a10.1111/dth.14128
000106602 0248_ $$2sideral$$a119647
000106602 037__ $$aART-2020-119647
000106602 041__ $$aeng
000106602 100__ $$aChernyshov, P.V.
000106602 245__ $$aInitial validation of the epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life questionnaire
000106602 260__ $$c2020
000106602 5060_ $$aAccess copy available to the general public$$fUnrestricted
000106602 5203_ $$aChildren with epidermolysis bullosa (EB) experienced the highest quality of life impact among several skin conditions and have problems which had not been reported by parents of children with other skin diseases. The EB-specific module of the Infants and Toddlers Dermatology Quality of Life (InToDermQoL) questionnaire was recently developed to measure the impact of disease-specific aspects in children from birth to the age of 4 years. The aim of this study was initial validation of the InToDermQoL-EB questionnaire. Parents of 44 children with EB from seven countries completed the InToDermQoL-EB questionnaire. Cronbach''s alpha was.86, .89 and.91 for three age-specific versions. Differences between severity levels were all significant except for that between moderate and severe level in the version for 3- to 4-year-old children. All items of the three versions of the InToDermQoL-EB showed very high levels of relevance except “problems with defecation” in children younger than 1 year and “rejection by other children” in 3- to 4-year-old children. The three versions of the InToDermQoL-EB instrument showed good internal consistency and discriminated well between different severity levels. All InToDermQoL-EB items were confirmed as being of high relevance and the questionnaire may be used in practice and clinical trials.
000106602 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000106602 590__ $$a2.851$$b2020
000106602 591__ $$aDERMATOLOGY$$b36 / 68 = 0.529$$c2020$$dQ3$$eT2
000106602 592__ $$a0.594$$b2020
000106602 593__ $$aMedicine (miscellaneous)$$c2020$$dQ2
000106602 593__ $$aDermatology$$c2020$$dQ2
000106602 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/submittedVersion
000106602 700__ $$0(orcid)0000-0001-5632-0351$$aMarron, S.E.$$uUniversidad de Zaragoza
000106602 700__ $$0(orcid)0000-0003-1917-6906$$aTomas-Aragones, L.$$uUniversidad de Zaragoza
000106602 700__ $$aPustišek, N.
000106602 700__ $$aGedeon, I.
000106602 700__ $$aSuru, A.
000106602 700__ $$aTiplica, G.S.
000106602 700__ $$aSalavastru, C.M.
000106602 700__ $$aNikolic, M.
000106602 700__ $$aKakourou, T.
000106602 700__ $$aValari, M.
000106602 700__ $$aYordanova, I.
000106602 700__ $$aDarlenski, R.
000106602 700__ $$aSampogna, F.
000106602 7102_ $$14009$$2735$$aUniversidad de Zaragoza$$bDpto. Psicología y Sociología$$cÁrea Psicolog.Evolut.Educac
000106602 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000106602 773__ $$g33, 6 (2020), e14128 [4 pp]$$pDermatologic Therapy$$tDermatologic Therapy$$x1396-0296
000106602 8564_ $$s377660$$uhttps://zaguan.unizar.es/record/106602/files/texto_completo.pdf$$yPreprint
000106602 8564_ $$s1468187$$uhttps://zaguan.unizar.es/record/106602/files/texto_completo.jpg?subformat=icon$$xicon$$yPreprint
000106602 909CO $$ooai:zaguan.unizar.es:106602$$particulos$$pdriver
000106602 951__ $$a2022-04-25-10:38:45
000106602 980__ $$aARTICLE